POTASSIUM PHOSPHATES Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Potassium Phosphates patents expire, and when can generic versions of Potassium Phosphates launch?
Potassium Phosphates is a drug marketed by Cmp Dev Llc and Fresenius Kabi Usa and is included in two NDAs. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There are two hundred and forty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.
DrugPatentWatch® Generic Entry Outlook for Potassium Phosphates
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 19, 2039. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for POTASSIUM PHOSPHATES
International Patents: | 1 |
US Patents: | 1 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in POTASSIUM PHOSPHATES? | POTASSIUM PHOSPHATES excipients list |
DailyMed Link: | POTASSIUM PHOSPHATES at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for POTASSIUM PHOSPHATES
Generic Entry Date for POTASSIUM PHOSPHATES*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for POTASSIUM PHOSPHATES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mahidol University | N/A |
Pharmacology for POTASSIUM PHOSPHATES
Drug Class | Osmotic Laxative Potassium Salt |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
US Patents and Regulatory Information for POTASSIUM PHOSPHATES
POTASSIUM PHOSPHATES is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of POTASSIUM PHOSPHATES is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting POTASSIUM PHOSPHATES
Potassium phosphates composition for injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
International Patents for POTASSIUM PHOSPHATES
See the table below for patents covering POTASSIUM PHOSPHATES around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2020081118 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for POTASSIUM PHOSPHATES
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0733366 | SPC/GB98/031 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
1718641 | SPC/GB12/028 | United Kingdom | See Plans and Pricing | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
1441735 | SPC/GB08/020 | United Kingdom | See Plans and Pricing | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
1718641 | 2012/008 | Ireland | See Plans and Pricing | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
0480717 | 98C0025 | Belgium | See Plans and Pricing | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
1499331 | SPC/GB13/034 | United Kingdom | See Plans and Pricing | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
0253310 | SPC/GB95/010 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |